ATE486087T1 - Fgf-5-bindende und geträgerte peptide - Google Patents

Fgf-5-bindende und geträgerte peptide

Info

Publication number
ATE486087T1
ATE486087T1 AT04818640T AT04818640T ATE486087T1 AT E486087 T1 ATE486087 T1 AT E486087T1 AT 04818640 T AT04818640 T AT 04818640T AT 04818640 T AT04818640 T AT 04818640T AT E486087 T1 ATE486087 T1 AT E486087T1
Authority
AT
Austria
Prior art keywords
peptides
supported
preferred embodiments
fgf
binding
Prior art date
Application number
AT04818640T
Other languages
English (en)
Inventor
Anthony G Day
David A Estell
Christopher J Murray
Scott D Power
Beverly R Turnquest
Original Assignee
Danisco Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danisco Us Inc filed Critical Danisco Us Inc
Application granted granted Critical
Publication of ATE486087T1 publication Critical patent/ATE486087T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
AT04818640T 2003-11-06 2004-11-06 Fgf-5-bindende und geträgerte peptide ATE486087T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US51815403P 2003-11-06 2003-11-06
US52040303P 2003-11-13 2003-11-13
US53095403P 2003-12-19 2003-12-19
US53118903P 2003-12-19 2003-12-19
US53120703P 2003-12-19 2003-12-19
PCT/US2004/036980 WO2005047314A2 (en) 2003-11-06 2004-11-06 Fgf-beta binding and supported peptides

Publications (1)

Publication Number Publication Date
ATE486087T1 true ATE486087T1 (de) 2010-11-15

Family

ID=34596198

Family Applications (4)

Application Number Title Priority Date Filing Date
AT04810431T ATE530560T1 (de) 2003-11-06 2004-11-06 Vegf bindende und geträgerte peptide zur behandlung von hautkrankheiten
AT04818640T ATE486087T1 (de) 2003-11-06 2004-11-06 Fgf-5-bindende und geträgerte peptide
AT04800809T ATE513917T1 (de) 2003-11-06 2004-11-06 Bakterielle expression von proteaseinhibitoren und varianten davon
AT04810432T ATE482972T1 (de) 2003-11-06 2004-11-06 Tgf-beta1-bindende und geträgerte peptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04810431T ATE530560T1 (de) 2003-11-06 2004-11-06 Vegf bindende und geträgerte peptide zur behandlung von hautkrankheiten

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT04800809T ATE513917T1 (de) 2003-11-06 2004-11-06 Bakterielle expression von proteaseinhibitoren und varianten davon
AT04810432T ATE482972T1 (de) 2003-11-06 2004-11-06 Tgf-beta1-bindende und geträgerte peptide

Country Status (9)

Country Link
US (8) US20080113917A1 (de)
EP (4) EP1692160B1 (de)
JP (2) JP4843497B2 (de)
AT (4) ATE530560T1 (de)
CA (1) CA2544820C (de)
DE (2) DE602004029393D1 (de)
DK (2) DK1692158T3 (de)
ES (1) ES2375360T3 (de)
WO (4) WO2005047511A2 (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544820C (en) * 2003-11-06 2014-02-18 Genencor International, Inc. Bacterial expression of protease inhibitors and variants thereof
EP1689766B1 (de) * 2003-11-06 2012-04-25 Danisco US Inc. Expression von proteaseinhibitoren und varianten davon in filamentösen pilzen
JP5255841B2 (ja) * 2004-10-15 2013-08-07 ジェネンコー・インターナショナル・インク 競合示差スクリーニング
BRPI0613548A2 (pt) * 2005-05-05 2011-01-18 Genencor Int composições de cuidado pessoal e métodos para seu uso
ATE477272T1 (de) 2005-06-10 2010-08-15 Medical Res Council Verwendung von stefin a als gerüstprotein
MX2008000230A (es) * 2005-07-13 2008-04-07 Amgen Mountain View Inc Proteinas de enlace il-6.
GB0601684D0 (en) * 2006-01-27 2006-03-08 Reckitt Benckiser Uk Ltd Composition, process for preparation and method of use
WO2007092465A2 (en) * 2006-02-07 2007-08-16 Dyao Pharmaceutical Corporation Topical delivery compositions
CA2664066C (en) * 2006-09-16 2017-04-18 Soy Labs Llc Products and methods using soy peptides to lower total and ldl cholesterol levels
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20080090745A1 (en) * 2006-10-13 2008-04-17 Fox Bryan P Expression of Streptomyces subtilism inhibitor (SSI) proteins in Bacillus and Streptomyces sp.
WO2008076323A2 (en) * 2006-12-18 2008-06-26 Danisco Us, Inc., Genencor Division Laccase mediators and methods of use
WO2008088493A2 (en) 2006-12-21 2008-07-24 Danisco Us, Inc., Genencor Division Compositions and uses for an alpha-amylase polypeptide of bacillus species 195
WO2008153925A2 (en) * 2007-06-06 2008-12-18 Danisco Us, Inc., Genencor Division Methods for improving multiple protein properties
US20090048136A1 (en) * 2007-08-15 2009-02-19 Mcdonald Hugh C Kappa-carrageenase and kappa-carrageenase-containing compositions
CA2703951A1 (en) * 2007-10-31 2009-05-07 Danisco Us Inc. Use and production of neutral metalloproteases in a serine protease-free background
CA2704548A1 (en) * 2007-11-01 2009-05-07 Danisco Us Inc. Signal sequences and co-expressed chaperones for improving protein production in a host cell
GB0722332D0 (en) * 2007-11-14 2007-12-27 Reckitt Benckiser Uk Ltd Personal care article
WO2009096916A1 (en) * 2008-01-29 2009-08-06 Genencor International, Inc. Expression of streptomyces subtilisin inhibitor (ssi) proteins in bacillus and streptomyces sp.
MX2010008359A (es) 2008-02-04 2010-08-30 Danisco Us Inc Variantes de alfa-amilasa ts23 con propiedades alteradas.
US7772181B2 (en) 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors
US7803902B2 (en) 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors
CA2740197A1 (en) * 2008-10-15 2010-04-22 Danisco Us Inc. Modified variant bowman birk protease inhibitors
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US20120172275A1 (en) 2009-03-10 2012-07-05 Danisco Us Inc. Bacillus Megaterium Strain DSM90-Related Alpha-Amylases, and Methods of Use, Thereof
US20100247693A1 (en) * 2009-03-24 2010-09-30 Marini Jan L Cosmetic formulation to treat rosacea telangiectasia
CN102388131B (zh) 2009-04-08 2014-04-30 丹尼斯科美国公司 盐单胞菌属菌株WDG195相关α-淀粉酶及其使用方法
CA2759695C (en) 2009-04-24 2018-05-01 Danisco Us Inc. Proteases with modified pro regions
CA2760554A1 (en) * 2009-05-01 2010-11-04 Signal Investment And Management Co. Moisturizing antimicrobial composition
AR076941A1 (es) 2009-06-11 2011-07-20 Danisco Us Inc Cepa de bacillus para una mayor produccion de proteina
US20110052676A1 (en) * 2009-09-01 2011-03-03 James Vincent Gruber Composition For Delaying Cellular Senescence
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
GB0921001D0 (en) 2009-11-30 2010-01-13 Aqua Bio Technology Asa Products and uses
CN102762222B (zh) 2009-12-09 2015-11-25 丹尼斯科美国公司 包含蛋白酶变体的组合物和方法
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
CN103988973A (zh) * 2009-12-30 2014-08-20 索莱有限责任公司 大豆乳清蛋白组合物及其回收方法
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9687591B2 (en) 2010-03-31 2017-06-27 Agency For Science, Technology And Research Building stratified biomimetic tissues and organs using crosslinked ultrashort peptide hydrogel membranes
SG184345A1 (en) 2010-03-31 2012-11-29 Agency Science Tech & Res Amphiphilic linear peptide/peptoid and hydrogel comprising the same
US8999916B2 (en) 2010-03-31 2015-04-07 Agency For Science, Technology And Research Crosslinked peptide hydrogels
CN102858970B (zh) 2010-04-15 2017-07-21 丹尼斯科美国公司 包含变体蛋白酶的组合物和方法
WO2011140316A1 (en) 2010-05-06 2011-11-10 The Procter & Gamble Company Consumer products with protease variants
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
CN106065381B (zh) 2011-05-05 2019-07-26 宝洁公司 包含丝氨酸蛋白酶变体的组合物和方法
CA3194062A1 (en) 2011-05-05 2012-11-08 Danisco Us Inc. Compositions and methods comprising serine protease variants
CN103781903A (zh) 2011-08-31 2014-05-07 丹尼斯科美国公司 包含脂肪分解酶变体的组合物和方法
EP2794866A1 (de) 2011-12-22 2014-10-29 Danisco US Inc. Zusammensetzungen und verfahren mit einer variante eines lipolytischen enzyms
US9120841B2 (en) 2012-09-28 2015-09-01 Agency For Science, Technology And Research Amphiphilic linear peptidepeptoid and hydrogel comprising the same
CN110093330B (zh) 2012-10-12 2023-11-28 丹尼斯科美国公司 包含脂解酶变体的组合物和方法
EP2914720B1 (de) 2012-11-05 2022-08-31 Danisco US Inc. Zusammensetzungen und verfahren mit thermolysinproteasevarianten
WO2014100018A1 (en) 2012-12-19 2014-06-26 Danisco Us Inc. Novel mannanase, compositions and methods of use thereof
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP3004314B1 (de) 2013-05-29 2018-06-20 Danisco US Inc. Neuartige metalloproteasen
EP3260538B1 (de) 2013-05-29 2021-04-14 Danisco US Inc. Neuartige metalloproteasen
EP3004342B1 (de) 2013-05-29 2023-01-11 Danisco US Inc. Neuartige metalloproteasen
JP2016526880A (ja) 2013-05-29 2016-09-08 ダニスコ・ユーエス・インク 新規メタロプロテアーゼ
ES2956266T3 (es) 2013-07-19 2023-12-18 Danisco Us Inc Composiciones y procedimientos que comprenden una variante de enzima lipolítica
BR112016005286A2 (pt) 2013-09-12 2017-09-12 Danisco Us Inc composições e métodos compreendendo variantes de protease do clado lg12
WO2015054670A1 (en) 2013-10-11 2015-04-16 Genentech, Inc. Nsp4 inhibitors and methods of use
US20160250298A1 (en) 2013-11-01 2016-09-01 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
EP3514230B1 (de) 2013-12-13 2021-09-22 Danisco US Inc. Serinproteasen aus einer bacillus-spezies
EP3910057A1 (de) 2013-12-13 2021-11-17 Danisco US Inc. Serinproteasen des bazillus gibsonii-clade
US9737592B1 (en) * 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US20170096653A1 (en) 2014-03-21 2017-04-06 Danisco Us Inc. Serine proteases of bacillus species
DK3207129T3 (da) 2014-10-17 2020-02-24 Danisco Us Inc Serinproteaser af bacillus-arten
WO2016069552A1 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases
EP3212782B1 (de) 2014-10-27 2019-04-17 Danisco US Inc. Serinproteasen
EP4403631A3 (de) 2014-10-27 2024-10-30 Danisco US Inc. Serinproteasen
WO2016069557A1 (en) 2014-10-27 2016-05-06 Danisco Us Inc. Serine proteases of bacillus species
US20170335306A1 (en) 2014-10-27 2017-11-23 Danisco Us Inc. Serine proteases
DK3268471T3 (da) 2015-03-12 2019-12-02 Danisco Us Inc Sammensætninger og fremgangsmåder omfattende lg12-clade-proteasevarianter
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3872174B1 (de) 2015-05-13 2023-03-01 Danisco US Inc. Aprl-clade-protease-varianten and verwendungen davon
EP4234693A3 (de) 2015-06-17 2023-11-01 Danisco US Inc Bacillus-gibboni-clade-serin-proteasen
CA2989667A1 (en) 2015-06-17 2016-12-22 Danisco Us Inc. Proteases with modified propeptide regions
CN107022432A (zh) * 2016-01-29 2017-08-08 高露洁-棕榄公司 清洁组合物
WO2017192300A1 (en) 2016-05-05 2017-11-09 Danisco Us Inc Protease variants and uses thereof
JP7609549B2 (ja) 2016-05-31 2025-01-07 ダニスコ・ユーエス・インク プロテアーゼ変異体およびその使用
CN109563497A (zh) 2016-06-17 2019-04-02 丹尼斯科美国公司 蛋白酶变体及其用途
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20200392477A1 (en) 2016-12-21 2020-12-17 Danisco Us Inc. Protease variants and uses thereof
CN110312794B (zh) 2016-12-21 2024-04-12 丹尼斯科美国公司 吉氏芽孢杆菌进化枝丝氨酸蛋白酶
US11298391B1 (en) * 2017-04-27 2022-04-12 Lorenol Laboratories, Inc. Topical skin health improvement compositions and administrations thereof
US20200354708A1 (en) 2017-11-29 2020-11-12 Danisco Us Inc. Subtilisin variants having improved stability
EP3799601A1 (de) 2018-06-19 2021-04-07 Danisco US Inc. Subtilisinvarianten
EP3810767B1 (de) 2018-06-19 2026-07-15 Danisco US Inc. Subtilisin-varianten
WO2020046613A1 (en) 2018-08-30 2020-03-05 Danisco Us Inc Compositions comprising a lipolytic enzyme variant and methods of use thereof
WO2020088393A1 (zh) * 2018-10-31 2020-05-07 青岛蔚蓝生物集团有限公司 一种生产具有蛋白酶抗性的洗涤用酶的方法
US12509672B2 (en) 2018-11-28 2025-12-30 Danisco Us Inc. Subtilisin variants having improved stability
CN114174504B (zh) 2019-05-24 2026-04-17 丹尼斯科美国公司 枯草杆菌蛋白酶变体和使用方法
CN112062828B (zh) * 2019-06-10 2022-04-29 温州医科大学 Fgf-5多肽抑制剂及其生发应用
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
EP4090727A1 (de) 2020-01-13 2022-11-23 Danisco US Inc. Zusammensetzungen mit einer lipolytischen enzymvariante und verfahren zur verwendung davon
EP3872088A1 (de) * 2020-02-28 2021-09-01 Alganelle Verwendung von aprotinin als träger zum herstellen eines rekombinanten proteins, polypeptides oder peptids in algen
CN116323935A (zh) 2020-08-27 2023-06-23 丹尼斯科美国公司 用于清洁的酶和酶组合物
GB202019817D0 (en) * 2020-12-15 2021-01-27 Univ Oxford Innovation Ltd Ligand-binding polypeptides and uses thereof
CN113307857B (zh) * 2021-01-14 2022-11-01 艾时斌 从表皮生长因子、凝集素和Tat蛋白衍生的支架蛋白
WO2023278297A1 (en) 2021-06-30 2023-01-05 Danisco Us Inc Variant lipases and uses thereof
CN117916354A (zh) 2021-09-03 2024-04-19 丹尼斯科美国公司 用于清洁的衣物洗涤组合物
CN118679252A (zh) 2021-12-16 2024-09-20 丹尼斯科美国公司 枯草杆菌蛋白酶变体和使用方法
US20230365897A1 (en) 2021-12-16 2023-11-16 The Procter & Gamble Company Fabric and home care composition including a protease
JP7842216B2 (ja) 2021-12-16 2026-04-07 ザ プロクター アンド ギャンブル カンパニー プロテアーゼを含む自動食器洗浄組成物
EP4448750A2 (de) 2021-12-16 2024-10-23 Danisco US Inc. Subtilisinvarianten und verwendungen davon
US20250051748A1 (en) 2021-12-16 2025-02-13 Danisco Us Inc. Subtilisin variants and methods of use
EP4486858A1 (de) 2022-03-01 2025-01-08 Danisco US Inc. Enzyme und enzymzusammensetzungen zur reinigung
CN120112635A (zh) 2022-09-02 2025-06-06 丹尼斯科美国公司 枯草杆菌蛋白酶变体及其相关方法
CN119855892A (zh) 2022-09-02 2025-04-18 丹尼斯科美国公司 洗涤剂组合物及其相关方法
CN120303400A (zh) 2022-11-09 2025-07-11 丹尼斯科美国公司 枯草杆菌蛋白酶变体和使用方法
EP4658776A1 (de) 2023-02-01 2025-12-10 Danisco US Inc. Subtilisinvarianten und verfahren zur verwendung
JP2026503673A (ja) 2023-02-01 2026-01-29 ザ プロクター アンド ギャンブル カンパニー 酵素を含有する洗剤組成物
WO2024186819A1 (en) 2023-03-06 2024-09-12 Danisco Us Inc. Subtilisin variants and methods of use
WO2025071996A1 (en) 2023-09-28 2025-04-03 Danisco Us Inc. Variant cutinase enzymes with improved solubility and uses thereof
WO2025085351A1 (en) 2023-10-20 2025-04-24 Danisco Us Inc. Subtilisin variants and methods of use
WO2026024922A1 (en) 2024-07-25 2026-01-29 Danisco Us Inc. Subtilisin variants and methods of use
WO2026050315A1 (en) 2024-08-29 2026-03-05 Danisco Us Inc. Subtilisin variants and methods of use

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) * 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
DE2437090A1 (de) * 1974-08-01 1976-02-19 Hoechst Ag Reinigungsmittel
JPS51125468A (en) 1975-03-27 1976-11-01 Sanyo Chem Ind Ltd Method of preparing resins of high water absorbency
US4152416A (en) * 1976-09-17 1979-05-01 Marra Dorothea C Aerosol antiperspirant compositions delivering astringent salt with low mistiness and dustiness
US4421769A (en) * 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
FI69503C (fi) * 1984-03-13 1986-02-10 Neste Oy Ytbelagd bergsbehaollare eller tunnel
US5411873A (en) * 1984-05-29 1995-05-02 Genencor, Inc. Process for producing heterologous polypeptides
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5679543A (en) * 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US4937370A (en) * 1987-06-02 1990-06-26 The Procter & Gamble Company Novel chromophores, sunscreen compositions and methods for preventing sunburn
US4999186A (en) * 1986-06-27 1991-03-12 The Procter & Gamble Company Novel sunscreen agents, sunscreen compositions and methods for preventing sunburn
US5322770A (en) * 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
WO1988002025A1 (en) * 1986-09-17 1988-03-24 Sri International Expression vectors for bacilli
US5087372A (en) * 1989-03-24 1992-02-11 Asahi Kasei Kogyo Kabushiki Kaisha Method for removing heavy metal ions from contaminated water and a porous membrane usable therefor
US5011681A (en) * 1989-10-11 1991-04-30 Richardson-Vicks, Inc. Facial cleansing compositions
US5073371A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5073372A (en) * 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5436228A (en) * 1990-12-12 1995-07-25 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US5429950A (en) * 1992-03-30 1995-07-04 Genencor International, Inc. Heterologous gene expression in bacillus subtilis: fusion approach
GB9415421D0 (en) 1994-07-30 1994-09-21 Procter & Gamble Cosmetic compositions and processes for manufacture thereof
EP0794764B1 (de) 1994-11-28 1999-03-31 The Procter & Gamble Company Topische hautpflegemittel enthaltend verdickte polyolestern von carbonsaüren als haut konditionierende agentien
CN1214082A (zh) * 1996-03-12 1999-04-14 金克克国际有限公司 碱性纤维素酶及其生产方法
WO1997038708A1 (en) * 1996-04-18 1997-10-23 The General Hospital Corporation Modulating epithelial-mesenchymal interactions
US5827508A (en) * 1996-09-27 1998-10-27 The Procter & Gamble Company Stable photoprotective compositions
US5976838A (en) * 1996-12-18 1999-11-02 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
KR20000057166A (ko) 1996-11-22 2000-09-15 데이비드 엠 모이어 미용 조성물
DE19735587B4 (de) * 1997-08-16 2012-03-22 Eberhard-Karls-Universität Tübingen Universitätsklinikum Peptid mit radioprotektiver Wirkung, dieses enthaltende kosmetische oder pharmazeutische Zusammensetzung, für dieses kodierende Nukleinsäure, Herstellungsverfahren für dieses Peptid und die Verwendung als radioprotektives Agens
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
DE69902924T2 (de) * 1998-07-20 2003-05-28 Inoxell A/S, Horsholm Neue methoden zum auffinden von liganden- und ziel-biomolekülen
US5935556A (en) * 1998-07-30 1999-08-10 The Procter & Gamble Company Sunscreen compositions
US5989528A (en) 1998-07-30 1999-11-23 The Procter & Gamble Company Sunscreen compositions
JP3855042B2 (ja) * 1998-09-22 2006-12-06 独立行政法人産業技術総合研究所 毛髪の鑑別法
US5968485A (en) * 1998-10-16 1999-10-19 The Procter & Gamble Company UV protection compositions
US5972316A (en) * 1998-10-16 1999-10-26 The Procter & Gamble Company UV protection compositions
WO2000024371A1 (en) 1998-10-23 2000-05-04 The Procter & Gamble Company Skin care compositions
GB9825854D0 (en) * 1998-11-25 1999-01-20 Univ Bristol Peptide
JP3106191B1 (ja) * 1999-03-30 2000-11-06 工業技術院長 Ｆｇｆ−５の生理的機能制御ペプチド及び該ペプチドを含有する医薬組成物
US7090973B1 (en) * 1999-04-09 2006-08-15 Oscient Pharmaceuticals Corporation Nucleic acid sequences relating to Bacteroides fragilis for diagnostics and therapeutics
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20100293669A2 (en) * 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US6872563B1 (en) * 1999-10-05 2005-03-29 President And Fellows Of Harvard College Compositions and methods for production of disulfide bond containing proteins in host cells
US20020001825A1 (en) * 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
EP1360500B1 (de) * 2000-04-14 2010-01-13 Genencor International, Inc. Verfahren zur selektiven zielen
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US6822082B2 (en) * 2000-06-30 2004-11-23 Zymogenetics, Inc. Polynucleotides for mammalian secreted protein, Z1055G2P
US6537968B1 (en) * 2000-07-24 2003-03-25 Alphamed Pharmaceuticals Corp Treatment of lupus erythematosus
DE60138764D1 (de) * 2000-12-13 2009-07-02 Anaphore Inc Methode zur identifikation und isolation von peptide die andere moleküle binden aus kombinatorische proteinbibliotheken mit einer c-typ lectin-ähnlichen domäne als gerüststruktur
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
WO2002094867A2 (fr) * 2001-02-07 2002-11-28 Institut Pasteur Sequence du genome de photorhabdus luminescens souche tto1 et utilisations
US7556939B2 (en) * 2003-02-11 2009-07-07 Institut Pasteur Identification and characterization of racemases, definition of protein signatures, and a test for detecting D-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase
CA2544820C (en) * 2003-11-06 2014-02-18 Genencor International, Inc. Bacterial expression of protease inhibitors and variants thereof
EP1689766B1 (de) * 2003-11-06 2012-04-25 Danisco US Inc. Expression von proteaseinhibitoren und varianten davon in filamentösen pilzen
US7319142B1 (en) * 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
US7772181B2 (en) * 2008-10-15 2010-08-10 Danisco Us Inc. Personal care compositions comprising modified variant Bowman Birk Protease Inhibitors
US7803902B2 (en) * 2008-10-15 2010-09-28 Danisco Us Inc. Modified variant bowman birk protease inhibitors

Also Published As

Publication number Publication date
US7524816B2 (en) 2009-04-28
ATE482972T1 (de) 2010-10-15
US20130065829A1 (en) 2013-03-14
ES2375360T3 (es) 2012-02-29
EP1692158B1 (de) 2011-10-26
US20080269139A1 (en) 2008-10-30
WO2005047314A2 (en) 2005-05-26
WO2005046710A2 (en) 2005-05-26
DE602004029393D1 (de) 2010-11-11
US7413877B2 (en) 2008-08-19
EP1692159A2 (de) 2006-08-23
DK1692158T3 (da) 2012-02-06
EP1680507B1 (de) 2011-06-22
CA2544820C (en) 2014-02-18
EP1692159B1 (de) 2010-09-29
US20050203026A1 (en) 2005-09-15
ATE513917T1 (de) 2011-07-15
WO2005047511A2 (en) 2005-05-26
WO2005046710A3 (en) 2005-11-24
JP2008500805A (ja) 2008-01-17
EP1692158A2 (de) 2006-08-23
WO2005046709A3 (en) 2005-11-24
US20090111160A1 (en) 2009-04-30
US20050202535A1 (en) 2005-09-15
ATE530560T1 (de) 2011-11-15
DK1680507T3 (da) 2011-10-10
EP1692160A2 (de) 2006-08-23
JP2012024091A (ja) 2012-02-09
WO2005047314A3 (en) 2006-04-20
US20080113917A1 (en) 2008-05-15
WO2005046709A2 (en) 2005-05-26
US7696173B2 (en) 2010-04-13
US7485618B2 (en) 2009-02-03
DE602004029812D1 (de) 2010-12-09
US20050238607A1 (en) 2005-10-27
EP1692160B1 (de) 2010-10-27
EP1680507A2 (de) 2006-07-19
WO2005047511A3 (en) 2005-11-24
CA2544820A1 (en) 2005-05-26
JP4843497B2 (ja) 2011-12-21
JP5728329B2 (ja) 2015-06-03
US20110230405A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
DE602004029812D1 (de) Fgf-5-bindende und geträgerte peptide
WO2006121610A3 (en) Personal care compositions and methods for their use
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
BRPI0519430A2 (pt) hormânio do crescimento humano modificado
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
DE602004019965D1 (de) Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten
ATE508635T1 (de) Virusvektoren und ihre verwendung bei therapeutischen methoden
ATE529442T1 (de) Verbesserte humane interferon-moleküle und ihre verwendungen
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
WO2003076592A3 (en) Novel method for delivery and intracellular synthesis of sirna molecules
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
WO2004002418A3 (en) Compositions and methods comprising protein activated receptor antagonists
ATE363531T1 (de) Claudin polypeptide
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
ATE389670T1 (de) Selektive peptidische agonisten des vpac2- rezeptors
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
ATE368687T1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
WO2003093305A3 (en) Teneurin c-terminal associated peptides (tcap) and uses thereof
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties